GLP-1 Research Peptides Explained: The Incretin Class

“GLP-1 peptides” is shorthand for a class of research compounds studied for their interaction with incretin receptors — the receptors that, in human physiology, are involved in metabolic and glucose-regulation signaling. This article explains the receptor biology that gives the class its name, framed strictly as laboratory research.

What GLP-1, GIP, and glucagon receptors are

GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are incretin hormones; glucagon is a counter-regulatory hormone. Each acts on its own receptor. Research peptides in this class are characterized by which of these receptors they engage — some are single-receptor agonists, others are dual or triple agonists.

Single, dual, and triple agonists

• Single-receptor research peptides engage one receptor (for example, GLP-1).
• Dual agonists engage two receptors (for example, GLP-1 and GIP).
• Triple agonists engage three — GLP-1, GIP, and glucagon. Retatrutide is studied as a triple-receptor research peptide.

What is studied

In research models, compounds in this class are examined for their effects on receptor signaling, insulin-sensitivity pathways, and energy-regulation mechanisms in vitro. The breadth of receptor engagement (single vs. dual vs. triple) is a primary variable researchers compare.

As with all peptides on this site, these are research compounds. Nothing here describes weight, appetite, or metabolic effects in people; the literature referenced concerns controlled experimental systems, and the material is not for human consumption.

Related compounds on this site

Beyond the incretin receptors, several growth-hormone-axis research peptides — such as tesamorelin and sermorelin (GHRH analogs) — are studied for endocrine signaling and are sometimes grouped with metabolic research more broadly. Cagrilintide, an amylin analog, is studied for satiety-signaling pathways.